ST elevation myocardial infarction thienopyridine therapy: Difference between revisions

Jump to navigation Jump to search
Line 21: Line 21:
It is important to note that the following patient groups were excluded from participation in CLARITY, and the results of CLARITY are not applicable to these subgroups: patients over 75 years of age, those with [[creatinine]] > 2.5 mg/dL, patients with [[cardiogenic shock]], or patients who had previously undergone coronary artery bypass grafting ([[CABG]]). It should also be noted that the rate of PCI or CABG was high at 63%. This may be due to the fact protocol-mandated angiography was performed in countries with a high rate of [[adjunctive PCI]] such as Europe and the United States.
It is important to note that the following patient groups were excluded from participation in CLARITY, and the results of CLARITY are not applicable to these subgroups: patients over 75 years of age, those with [[creatinine]] > 2.5 mg/dL, patients with [[cardiogenic shock]], or patients who had previously undergone coronary artery bypass grafting ([[CABG]]). It should also be noted that the rate of PCI or CABG was high at 63%. This may be due to the fact protocol-mandated angiography was performed in countries with a high rate of [[adjunctive PCI]] such as Europe and the United States.


==Reduction in mortality associated with clopidogrel==
==Reduction in mortality associated with clopidogrel administration in conjunction with fibrinolytic agents: Results of COMMIT==
The COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group evaluated the safety and efficacy of clopidogrel as an adjuncti to fibrinolytic therapy in 45,852 patients. <ref name="pmid16271642">{{cite journal |author=Chen ZM, Jiang LX, Chen YP, ''et al'' |title=Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial |journal=Lancet |volume=366 |issue=9497 |pages=1607–21 |year=2005 |month=November |pmid=16271642 |doi=10.1016/S0140-6736(05)67660-X |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(05)67660-X}}</ref>
The COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group evaluated the safety and efficacy of clopidogrel as an adjuncti to fibrinolytic therapy in 45,852 patients. <ref name="pmid16271642">{{cite journal |author=Chen ZM, Jiang LX, Chen YP, ''et al'' |title=Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial |journal=Lancet |volume=366 |issue=9497 |pages=1607–21 |year=2005 |month=November |pmid=16271642 |doi=10.1016/S0140-6736(05)67660-X |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(05)67660-X}}</ref>
45,852 patients admitted to 1250 hospitals within 24 h of suspected acute MI onset were randomly allocated clopidogrel 75 mg daily (n=22,961) or matching placebo (n=22,891) in addition to aspirin 162 mg daily. 93% had ST-segment elevation or bundle branch block, and 7% had ST-segment depression. Treatment was to continue until discharge or up to 4 weeks in hospital (mean 15 days in survivors) and 93% of patients completed it. The two prespecified co-primary outcomes were: (1) the composite of death, reinfarction, or stroke; and (2) death from any cause during the scheduled treatment period. Comparisons were by intention to treat, and used the log-rank method. This trial is registered with ClinicalTrials.gov, number NCT00222573. FINDINGS: Allocation to clopidogrel produced a highly significant 9% (95% CI 3-14) proportional reduction in death, reinfarction, or stroke (2121 [9.2%] clopidogrel vs 2310 [10.1%] placebo; p=0.002), corresponding to nine (SE 3) fewer events per 1000 patients treated for about 2 weeks. There was also a significant 7% (1-13) proportional reduction in any death (1726 [7.5%] vs 1845 [8.1%]; p=0.03). These effects on death, reinfarction, and stroke seemed consistent across a wide range of patients and independent of other treatments being used. Considering all fatal, transfused, or cerebral bleeds together, no significant excess risk was noted with clopidogrel, either overall (134 [0.58%] vs 125 [0.55%]; p=0.59), or in patients aged older than 70 years or in those given fibrinolytic therapy. INTERPRETATION: In a wide range of patients with acute MI, adding clopidogrel 75 mg daily to aspirin and other standard treatments (such as fibrinolytic therapy) safely reduces mortality and major vascular events in hospital, and should be considered routinely.


==Dosing of clopidogrel==
==Dosing of clopidogrel==

Revision as of 19:57, 15 February 2009

WikiDoc Resources for ST elevation myocardial infarction thienopyridine therapy

Articles

Most recent articles on ST elevation myocardial infarction thienopyridine therapy

Most cited articles on ST elevation myocardial infarction thienopyridine therapy

Review articles on ST elevation myocardial infarction thienopyridine therapy

Articles on ST elevation myocardial infarction thienopyridine therapy in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on ST elevation myocardial infarction thienopyridine therapy

Images of ST elevation myocardial infarction thienopyridine therapy

Photos of ST elevation myocardial infarction thienopyridine therapy

Podcasts & MP3s on ST elevation myocardial infarction thienopyridine therapy

Videos on ST elevation myocardial infarction thienopyridine therapy

Evidence Based Medicine

Cochrane Collaboration on ST elevation myocardial infarction thienopyridine therapy

Bandolier on ST elevation myocardial infarction thienopyridine therapy

TRIP on ST elevation myocardial infarction thienopyridine therapy

Clinical Trials

Ongoing Trials on ST elevation myocardial infarction thienopyridine therapy at Clinical Trials.gov

Trial results on ST elevation myocardial infarction thienopyridine therapy

Clinical Trials on ST elevation myocardial infarction thienopyridine therapy at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on ST elevation myocardial infarction thienopyridine therapy

NICE Guidance on ST elevation myocardial infarction thienopyridine therapy

NHS PRODIGY Guidance

FDA on ST elevation myocardial infarction thienopyridine therapy

CDC on ST elevation myocardial infarction thienopyridine therapy

Books

Books on ST elevation myocardial infarction thienopyridine therapy

News

ST elevation myocardial infarction thienopyridine therapy in the news

Be alerted to news on ST elevation myocardial infarction thienopyridine therapy

News trends on ST elevation myocardial infarction thienopyridine therapy

Commentary

Blogs on ST elevation myocardial infarction thienopyridine therapy

Definitions

Definitions of ST elevation myocardial infarction thienopyridine therapy

Patient Resources / Community

Patient resources on ST elevation myocardial infarction thienopyridine therapy

Discussion groups on ST elevation myocardial infarction thienopyridine therapy

Patient Handouts on ST elevation myocardial infarction thienopyridine therapy

Directions to Hospitals Treating ST elevation myocardial infarction thienopyridine therapy

Risk calculators and risk factors for ST elevation myocardial infarction thienopyridine therapy

Healthcare Provider Resources

Symptoms of ST elevation myocardial infarction thienopyridine therapy

Causes & Risk Factors for ST elevation myocardial infarction thienopyridine therapy

Diagnostic studies for ST elevation myocardial infarction thienopyridine therapy

Treatment of ST elevation myocardial infarction thienopyridine therapy

Continuing Medical Education (CME)

CME Programs on ST elevation myocardial infarction thienopyridine therapy

International

ST elevation myocardial infarction thienopyridine therapy en Espanol

ST elevation myocardial infarction thienopyridine therapy en Francais

Business

ST elevation myocardial infarction thienopyridine therapy in the Marketplace

Patents on ST elevation myocardial infarction thienopyridine therapy

Experimental / Informatics

List of terms related to ST elevation myocardial infarction thienopyridine therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

There are at present two agents available in this class, Ticlopidine and clopidogrel. Prasugrel is currently an investigational drug in this class. These agents inhibit the ADP-receptor and thereby reduce platelet activation. As an adjunct to fibrinolytic therapy, clopidogrel has been associated with improved patency in the CLARITY trial (300 mg loading dose and 75 mg/day maintenance dose), and a reduction in mortality in the COMMIT trial (75 mg/day loading and maintenance dose). Among STEMI patients treated with a fibrinolytic agent, co-administration of clopidogrel at a loading dose of 300 mg and a maintenance dose of 75 mg/day should be viewed as the standard of care.

Angiographic efficacy of Clopidogrel as adjunctive therapy to fibrinolysis in STEMI patients

The angiographic effectiveness of clopidogrel as adjunctive therapy to fibrinolytic administration was evaluated in the Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-TIMI 28 trial. [1] [2] [3] This study randomized 3,491 STEMI patients to treatement with either placebo or a 300 mg loading dose of clopidogrel followed by a maintenance dose of 75 mg/day. The trial demonstrated a 35% relative risk reduction in the incidence of an occluded artery on angiography, death, or MI associated with clopidogrel administration. [1]

Safety of Clopidogrel in CLARITY

Clopidogrel administration was not associated with an increase in TIMI major bleeding or intracranial hemorrhage (ICH). Indeed, the incidence of all causes of stroke was reduced by 46% (P = 0.052).

Generalizability of results from CLARITY

There was no heterogeneity in the treatment benefit (that is a consistent benefit was observed) irrespective of:

  1. Type of fibrinolytic (2/3rds of patients were treated with a fibrin-specific agent such as tPA, rPA, nPA, or TNK) or
  2. Tyep of antithrombin administered (45.8% received UFH, 29.6% received enoxaparin, 24.5% received both or none).

It is important to note that the following patient groups were excluded from participation in CLARITY, and the results of CLARITY are not applicable to these subgroups: patients over 75 years of age, those with creatinine > 2.5 mg/dL, patients with cardiogenic shock, or patients who had previously undergone coronary artery bypass grafting (CABG). It should also be noted that the rate of PCI or CABG was high at 63%. This may be due to the fact protocol-mandated angiography was performed in countries with a high rate of adjunctive PCI such as Europe and the United States.

Reduction in mortality associated with clopidogrel administration in conjunction with fibrinolytic agents: Results of COMMIT

The COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group evaluated the safety and efficacy of clopidogrel as an adjuncti to fibrinolytic therapy in 45,852 patients. [4] 45,852 patients admitted to 1250 hospitals within 24 h of suspected acute MI onset were randomly allocated clopidogrel 75 mg daily (n=22,961) or matching placebo (n=22,891) in addition to aspirin 162 mg daily. 93% had ST-segment elevation or bundle branch block, and 7% had ST-segment depression. Treatment was to continue until discharge or up to 4 weeks in hospital (mean 15 days in survivors) and 93% of patients completed it. The two prespecified co-primary outcomes were: (1) the composite of death, reinfarction, or stroke; and (2) death from any cause during the scheduled treatment period. Comparisons were by intention to treat, and used the log-rank method. This trial is registered with ClinicalTrials.gov, number NCT00222573. FINDINGS: Allocation to clopidogrel produced a highly significant 9% (95% CI 3-14) proportional reduction in death, reinfarction, or stroke (2121 [9.2%] clopidogrel vs 2310 [10.1%] placebo; p=0.002), corresponding to nine (SE 3) fewer events per 1000 patients treated for about 2 weeks. There was also a significant 7% (1-13) proportional reduction in any death (1726 [7.5%] vs 1845 [8.1%]; p=0.03). These effects on death, reinfarction, and stroke seemed consistent across a wide range of patients and independent of other treatments being used. Considering all fatal, transfused, or cerebral bleeds together, no significant excess risk was noted with clopidogrel, either overall (134 [0.58%] vs 125 [0.55%]; p=0.59), or in patients aged older than 70 years or in those given fibrinolytic therapy. INTERPRETATION: In a wide range of patients with acute MI, adding clopidogrel 75 mg daily to aspirin and other standard treatments (such as fibrinolytic therapy) safely reduces mortality and major vascular events in hospital, and should be considered routinely.

Dosing of clopidogrel

Data from the non-ST elevation MI population does demonstrate that a 600 mg oral dose achieves sustained inhibition more rapidly than a 300 mg dose. A 600 mg dose does not, however, achieve a higher level of inhibition. The FDA package insert loading dose is 300 mg, but in clinical practice both 300 and 600 mg doses are used. A loading dose of 600 mg of clopidogrel has not been studied in conjunction with fibrinolytic therapy and cannot be recommended.

Side effects of thienopyridines

Ticlopidine administration has been associated with neutropenia and thrombotic thrombocytopenia (TTP). It is as a result of these potential side effects that clopidogrel is often prescribed instead. Clopidogrel may also be preferred because of the lack of need for laboratory monitoring, and once-daily dosing. It should be noted, however, that approximately one third to one quarter of patients may be resistant to clopidogrel, which is a pro-drug. For those patients who develop stent thrombosis while on clopidogrel, ticlopidine may be an optimal substitution because it is not a pro-drug and is not metabolized by the same pathway as clopidogrel.

ACC / AHA Guidelines (DO NOT EDIT)

  • Class I

1. In patients who have undergone diagnostic cardiac catheterization and for whom PCI is planned, clopidogrel should be started and continued for at least 1 month after bare metal stent implantation, for several months after drug-eluting stent implantation (3 months for sirolimus, 6 months for paclitaxel), and up to 12 months in patients who are not at high risk for bleeding. (Level of Evidence: B)

2. In patients taking clopidogrel in whom CABG is planned, the drug should be withheld for at least 5 days, and preferably for 7 days, unless the urgency for revascularization outweighs the risks of excess bleeding. (Level of Evidence: B)

  • Class IIa

Clopidogrel is probably indicated in patients receiving fibrinolytic therapy who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance. (Level of Evidence: C)

References

  1. 1.0 1.1 Sabatine MS, Cannon CP, Gibson CM; et al. (2005). "Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation". N. Engl. J. Med. 352 (12): 1179–89. doi:10.1056/NEJMoa050522. PMID 15758000. Unknown parameter |month= ignored (help)
  2. Sabatine MS, Morrow DA, Montalescot G; et al. (2005). "Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial". Circulation. 112 (25): 3846–54. doi:10.1161/CIRCULATIONAHA.105.595397. PMID 16291601. Unknown parameter |month= ignored (help)
  3. Gibson CM, Murphy SA, Pride YB; et al. (2008). "Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study". Am. Heart J. 155 (1): 133–9. doi:10.1016/j.ahj.2007.08.034. PMID 18082504. Unknown parameter |month= ignored (help)
  4. Chen ZM, Jiang LX, Chen YP; et al. (2005). "Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial". Lancet. 366 (9497): 1607–21. doi:10.1016/S0140-6736(05)67660-X. PMID 16271642. Unknown parameter |month= ignored (help)

Template:WH Template:WikiDoc Sources